Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | ME2 | P23368 | 2/20 | 0.43 |
| ▸ | ME1 | P48163 | 2/20 | 0.43 |
| ▸ | ME3 | Q16798 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989360 | 0.88 | NPC1 (0.46) | NPC1ALDH1A1ME2ME1ME3 | |
| SCHEMBL4988637 | 0.83 | GRM5 (0.48) | ALDH1A1PTGDR2 | |
| SCHEMBL4980953 | 0.81 | MEN1 (0.53) | NPC1TDP1ALDH1A1POLBME2 | |
| SCHEMBL4985624 | 0.79 | P2RX7 (0.49) | ALDH1A1 | |
| SCHEMBL4984698 | 0.79 | F12 (0.42) | NPC1 | |
| SCHEMBL4984972 | 0.77 | RAB9A (0.38) | NPC1TDP1ALDH1A1 | |
| SCHEMBL4982529 | 0.77 | ALDH1A1 (0.42) | ALDH1A1ENPP2 | |
| SCHEMBL4986049 | 0.77 | POLB (0.45) | NPC1ALDH1A1POLBENPP2ME2 | |
| SCHEMBL4989572 | 0.76 | P2RX7 (0.44) | ALDH1A1TSHR | |
| SCHEMBL14272299 | 0.76 | TSHR (0.53) | NPC1TDP1GPBAR1POLBENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | NPC1 2233/4885TDP1 2440/4885GPBAR1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.